<DOC>
	<DOCNO>NCT00366275</DOCNO>
	<brief_summary>The purpose study determine rate duration complete remission molecular response patient relapsed/refractory follicular lymphoma , use combine treatment rituximab plus chemotherapy follow vivo purge peripheral blood stem cell ( PBSC ) mobilization autotransplant .</brief_summary>
	<brief_title>Immunochemotherapy , Vivo Purging , PBSC Mobilization Autotransplant Relapsed Refractory Follicular Lymphoma</brief_title>
	<detailed_description>Autologous stem cell transplantation show effective long-term control follicular lymphoma . Lymphoma , however , progress high-dose treatment . Lymphoma cell prove contaminate bone marrow peripheral blood stem cell ( PBSC ) collection may contribute relapse autotransplant . The presence peripheral blood marrow PCR-detectable cell bear bcl-2 rearrangement appear surrogate marker disease achievement bcl-2 negative status associate low risk recurrence . Several method attempt abolish graft contamination : vitro treatment cytotoxic agent , vitro treatment anti-B-cell monoclonal antibody complement , immunomagnetic bead , positive selection CD34+ cell . All technique usually produce loss cell , time-consuming expensive , neoplastic depletion often partial residual polymerase chain reaction ( PCR ) -positive cell graft . In last year chimeric anti-CD20 monoclonal antibody Rituximab show effective therapeutic option low-grade lymphoma . Owing different mechanism action , synergism cytotoxic agent , non-overlapping toxicity , Rituximab ideal drug combination chemotherapy . On basis , Rituximab use mobilisation procedure tool obtain vivo purge collection lymphoma-free progenitor cell . In addition , several study demonstrate efficiency peripheral blood stem cell ( PBSC ) harvest adversely affected Rituximab engraftment parameter hematopoietic recovery compromise . The incorporation Rituximab sequential high-dose therapy program produce high rate clinical molecular remission patient indolent lymphoma , indicate antibody additive effect chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients relapse refractory follicular lymphoma chemotherapy Patients relapse refractory follicular lymphoma rituximab single agent chemotherapy Patients transform follicular lymphoma CD20positivity Age 18 60 year Advanced Ann Arbor stage Normal cardiac , renal hepatic function Negativity human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Total amount anthracycline previously receive &lt; 300 mg/m^2 Exclusion criterion : Creatinine &gt; 2 mg/dl Alanine transaminase ( ALT ) alkaline phosphatase &gt; 2N Cardiac pulmonary disease Severe organic psychiatric disease Positivity human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Pregnancy , breastfeed Cancer diagnosis 5 year lymphoma diagnosis , except nonmelanoma skin cancer Cervical Intraepithelial Neoplasia ( CIN )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>follicular lymphoma</keyword>
	<keyword>rituximab</keyword>
	<keyword>immunochemotherapy</keyword>
	<keyword>peripheral blood stem cell ( PBSC ) mobilization</keyword>
	<keyword>vivo purging</keyword>
	<keyword>autotransplant</keyword>
	<keyword>bcl-2 rearrangement</keyword>
	<keyword>molecular response</keyword>
</DOC>